Repeated cycles of rozanolixizumab treatment in patients with muscle-specific kinase autoantibody-positive generalized myasthenia gravis

Important Information Related to Your Request:

The material below is provided in response to your specific search for information on UCBCOMPASS^® and may contain information that is not part of the FDA-approved Prescribing Information. UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please review the Full Prescribing Information.

Study Limitations: Studies MG0004 (NCT04124965) and MG0007 (NCT04650854) were designed to evaluate safety and were not placebo controlled, therefore efficacy or clinical significance should be interpreted with caution.